Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 89.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,766 shares of the company's stock after selling 245,678 shares during the period. Squarepoint Ops LLC's holdings in Twist Bioscience were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Barclays PLC boosted its stake in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after buying an additional 104,420 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after acquiring an additional 189,791 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Twist Bioscience by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock valued at $1,761,000 after acquiring an additional 9,722 shares during the period. KBC Group NV raised its holdings in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after purchasing an additional 1,226 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Twist Bioscience by 18.9% in the fourth quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock valued at $807,000 after acquiring an additional 2,755 shares in the last quarter.

Twist Bioscience Stock Down 1.4%

Shares of TWST traded down $0.44 on Wednesday, reaching $30.44. The stock had a trading volume of 1,019,898 shares, compared to its average volume of 982,351. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12-month low of $27.12 and a 12-month high of $60.90. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.01 and a beta of 2.54. The company has a 50-day simple moving average of $34.66 and a 200-day simple moving average of $42.09.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 689 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares in the company, valued at $4,173,464.85. The trade was a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 918 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,850 shares of company stock valued at $974,764 in the last ninety days. Corporate insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on TWST. Guggenheim reissued a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.